ReviewCancer immunology research2015
Neoepitopes of Cancers: Looking Back, Looking Ahead.
Review in Cancer immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 79 citations in OpenAlex.
- TAP1 deficiency reshapes tumor antigenicity and enables CD8 T cell targeting in colorectal cancer.Molecular therapy. Oncology · 2026Article
- The landscape of genitourinary cancer vaccines: clinical advances and future opportunities.Journal of advanced research · 2026Review
- Reversing the "cold" tumor microenvironment: the role of neoantigen vaccines in prostate cancer.Journal of translational medicine · 2025Article
- Cancer Vaccines: A Novel Revolutionized Approach to Cancer Therapy.Indian journal of clinical biochemistry : IJCB · 2025Review
- Advances and challenges in neoantigen prediction for cancer immunotherapy.Frontiers in immunology · 2025Review
- Vaccine approaches to treat urothelial cancer.Human vaccines & immunotherapeutics · 2024Review
- Review
- The immunosuppressive landscape in tumor microenvironment.Immunologic research · 2024Review
- Tumor neoantigens and tumor immunotherapies.Aging medicine (Milton (N.S.W)) · 2024Review
- Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy.Asian journal of pharmaceutical sciences · 2024Review
- Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.NPJ precision oncology · 2024Article
- DNA vaccines as promising immuno-therapeutics against cancer: a new insight.Frontiers in immunology · 2024Review
- Prospective Identification of Prognostic Hot-Spot Mutant Gene Signatures for Leukemia: A Computational Study Based on Integrative Analysis of TCGA and cBioPortal Data.Molecular biotechnology · 2023Article
- Heterogeneity of the tumor immune microenvironment and clinical interventions.Frontiers of medicine · 2023Review
- mRNA-From COVID-19 Treatment to Cancer Immunotherapy.Biomedicines · 2023Review
- Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer.Frontiers in immunology · 2023Review
- Development of therapeutic vaccines for the treatment of diseases.Molecular biomedicine · 2022Review
- The foundations of immune checkpoint blockade and the ipilimumab approval decennial.Nature reviews. Drug discovery · 2022Review
- Role of CD68 in tumor immunity and prognosis prediction in pan-cancer.Scientific reports · 2022Article
- New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis.Journal for immunotherapy of cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The search for specificity in cancers has been a holy grail in cancer immunology. Cancer geneticists have long known that cancers harbor transforming and other mutations. Immunologists have long known that inbred mice can be immunized against syngeneic cancers, indicating the existence of cancer-specific antigens. With the technological advances in high-throughput DNA sequencing and bioinformatics, the genetic and immunologic lines of inquiry are now converging to provide definitive evidence that human cancers are vastly different from normal tissues at the genetic level, and that some of these differences are recognized by the immune system. The very vastness of genetic changes in cancers now raises different question. Which of the many cancer-specific genetic (genomic) changes are actually recognized by the immune system, and why? New observations are now beginning to probe these vital issues with unprecedented resolution and are informing a new generation of studies in human cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.